DE69033457T2 - Prohormonspaltungsplatzblockierungsantikörper - Google Patents

Prohormonspaltungsplatzblockierungsantikörper

Info

Publication number
DE69033457T2
DE69033457T2 DE69033457T DE69033457T DE69033457T2 DE 69033457 T2 DE69033457 T2 DE 69033457T2 DE 69033457 T DE69033457 T DE 69033457T DE 69033457 T DE69033457 T DE 69033457T DE 69033457 T2 DE69033457 T2 DE 69033457T2
Authority
DE
Germany
Prior art keywords
prohormone
prohormon
blocking antibodies
closure blocking
closure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69033457T
Other languages
English (en)
Other versions
DE69033457D1 (en
Inventor
Michael Kriegler
Carl Perez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE69033457D1 publication Critical patent/DE69033457D1/de
Application granted granted Critical
Publication of DE69033457T2 publication Critical patent/DE69033457T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69033457T 1989-08-16 1990-08-13 Prohormonspaltungsplatzblockierungsantikörper Expired - Lifetime DE69033457T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39525489A 1989-08-16 1989-08-16
PCT/US1990/004536 WO1991002756A1 (en) 1989-08-16 1990-08-13 Prohormone cleavage site blocking antibody

Publications (2)

Publication Number Publication Date
DE69033457D1 DE69033457D1 (en) 2000-03-16
DE69033457T2 true DE69033457T2 (de) 2000-09-14

Family

ID=23562288

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69033457T Expired - Lifetime DE69033457T2 (de) 1989-08-16 1990-08-13 Prohormonspaltungsplatzblockierungsantikörper

Country Status (8)

Country Link
US (3) US5677182A (de)
EP (1) EP0487610B1 (de)
JP (1) JPH05501351A (de)
AT (1) ATE189682T1 (de)
AU (1) AU641178B2 (de)
CA (1) CA2023250A1 (de)
DE (1) DE69033457T2 (de)
WO (1) WO1991002756A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000074I1 (de) * 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
EP0657469A1 (de) * 1993-10-26 1995-06-14 Boehringer Ingelheim Pharmaceuticals Inc. L-Selektinspaltungsplatz, Verfahren zur Diagnose une ihre Verwendung
NZ510390A (en) * 1995-06-08 2002-11-26 Immunex Corp TNF-alpha converting enzyme
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
US5830742A (en) * 1995-06-08 1998-11-03 Immunex Corporation TNF-α converting enzyme
IL114461A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev TNF modulation
CN1310675C (zh) * 1995-07-20 2007-04-18 依默耐克斯有限公司 TNF－α转变酶
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
CN100434440C (zh) 2002-12-02 2008-11-19 阿布格尼克斯公司 针对肿瘤坏死因子的抗体及其用途
JP4769456B2 (ja) * 2004-12-27 2011-09-07 昭和シェル石油株式会社 ウレア系潤滑グリース組成物、転がり軸受けおよび電動パワーステアリング装置
JP2010528647A (ja) 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
RU2571212C2 (ru) 2009-02-19 2015-12-20 Мерц Фарма Гмбх Унд Ко. Кгаа Средства и способы получения высокоочищенного нейротоксина
KR101818777B1 (ko) * 2009-04-27 2018-01-15 메르츠 파마 게엠베하 운트 코. 카가아 신경독 폴리펩티드의 양 및 이들의 촉매 활성 및 단백질 분해 활성의 결정수단 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0288088B1 (de) * 1987-04-24 1994-03-09 Teijin Limited Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung
AU626572B2 (en) * 1988-07-18 1992-08-06 Chiron Corporation Monoclonal antibodies reactive with cachectin
DE10399036I1 (de) * 1989-08-07 2004-04-01 Peptide Technology Ltd Bindeligande für Tumornekrosisfaktor.

Also Published As

Publication number Publication date
DE69033457D1 (en) 2000-03-16
AU641178B2 (en) 1993-09-16
WO1991002756A1 (en) 1991-03-07
CA2023250A1 (en) 1991-02-16
JPH05501351A (ja) 1993-03-18
US5702705A (en) 1997-12-30
US5686259A (en) 1997-11-11
US5677182A (en) 1997-10-14
ATE189682T1 (de) 2000-02-15
EP0487610A1 (de) 1992-06-03
EP0487610B1 (de) 2000-02-09
AU6276590A (en) 1991-04-03

Similar Documents

Publication Publication Date Title
DE69033457T2 (de) Prohormonspaltungsplatzblockierungsantikörper
BR9710811A (pt) Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
DE69426743D1 (de) Bispezifische Auslösemoleküle, die das Lymphozytantigen CD2 und Tumorantigene erkennen
DE69729283D1 (de) GLYKOSYLIERTE IgG ANTIKÖRPER
DE69942148D1 (de) Gebrauch von bispezifischen antikörpern in diagnose und therapie
EP0160250A3 (de) Monoklonale Antikörpersammlung zur Frühdiagnose und Behandlung von Nierenkarzinomen
DE69228701D1 (de) Fragmente von Prion Proteinen.
DE1257584T1 (de) Humanisierte antikörper, die amyloid beta peptid demarkieren
NZ217829A (en) Monoclonal anti-human breast cancer antibodies and test reagent
CA2163032A1 (en) Antibody Fragments in Therapy
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
ES2156859T3 (es) Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano.
EP0938505A4 (de) Monoklonale antikörper gegen endoglin und ihre verwendung in der antiangiogenen therapie
ES2114064T3 (es) Inmunoanalisis para la deteccion de colageno o fragmentos de colageno.
ES2033823T3 (es) Ensayo en cuanto a cancer de mama humano.
DE60029953D1 (de) Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose
Kelly et al. Antibody to discrete areas of the brain in normal individuals and patients with schizophrenia.
DE69030545T2 (de) Aufspüren und Behandeln von Infektionen durch Verwendung von Immunokonjukaten
IT1264083B1 (it) Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
Ablin Demonstration of intercellular and basement-membrane zone antibodies in benign prostatic hypertrophy
Parker et al. CA 125 and survival in ovarian cancer: preliminary communication
CA2054689A1 (en) An immunoassay method for determining the specificity of binding of a monoclonal antibody to an antigen
ATE97324T1 (de) Verwendung von amphipatischen molekuelen zur radiodarstellung und therapie mittels monoklonaler oder polyklonaler antikoerperkonjugate.
DE69229948T2 (de) hGPIIb-FRAGMENTE UND IHRE VERWENDUNG IN IN-VITRO-VERFAHREN ZUR BESTIMMUNG VON IN VIVO STATTFINDENDEN THROMBOTISCHEN EREIGNISSEN

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US